Abstract: Though renin-angiotensin-aldosterone system (RAAS) blockers have been considered the primary treatment for patients with Alport syndrome (AS) for a decade, there is no comprehensive review with evidencebased analysis evaluating the effectiveness of RAAS blockers in AS. Since 2020, several cohort studies have shown some positive effects of RAAS blockers on improving renal outcomes in patients with AS. A newly published systematic review and meta-analysis summarized all available data from comparative studies and systematically evaluated the effectiveness of RAAS blockers in AS for the first time, which provided data support for improving decisions about the clinical practice of AS.

Key words: renin-angiotensin-aldosterone system blockers, Alport syndrome, meta-analysis, cohort study